Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
Patents for C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
11/2005
11/30/2005EP1599465A1 Substituted n-aryl nitrogen heterocycles
11/30/2005EP1599451A1 Pesticidal 1-ayl-3-amidoxime-pyrazole derivatives
11/30/2005EP1599200A2 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
11/30/2005EP1599167A2 Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament
11/30/2005EP1599096A2 Hetero substitued sodium channel blockers
11/30/2005EP1511385B1 Insecticidal amides with nitrogen-containing benzo-fused bicyclic ring systems
11/30/2005EP1458381B1 Triazoles as oxytocin antagonists
11/30/2005EP1146877B1 (2-imidazolin-2-ylamino) quinoxalines for the treatment of neural injury
11/30/2005EP1140786B1 Reductive alkylation of secondary amines with hydrosilane
11/30/2005EP1124827B1 3-(substituted phenyl)-5-(substituted heterocyclyl)-1,2,4-triazole compounds
11/30/2005EP1091943B1 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
11/30/2005EP0920424B1 Non-peptide bombesin receptor antagonists
11/30/2005CN1703412A Novel compounds with antibacterial activity
11/30/2005CN1703405A Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors
11/30/2005CN1703402A Pyridine derivatives as CB2 receptor modulators
11/30/2005CN1703395A Aryl and heteroaryl compounds and methods to modulate coagulation
11/30/2005CN1703221A 2-alkyl-(2-amino-3-aryl-propionyl)-piperazine derivatives and related compounds as melanocortin receptor ligands for the treatment of obesity
11/30/2005CN1702065A Fluorene-based compound and organic electroluminescent display device using the same
11/30/2005CN1229374C Substituted bisindolylmaleimides for inhibition of cell proliferation
11/30/2005CN1229358C Novel tetrazolinone derivatives
11/30/2005CN1229353C Method and compositions utilizing quinazolinones
11/30/2005CN1229351C Heterocyclic compounds and methods to treat cardiac failure and other disorders
11/30/2005CN1229345C N-(indolcarbonyl) piperazin derivatives
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229336C Photoactive compound used as intermediate for preparing photoactive 2-imidazoline-5-ketone or 2-imdazoline-5-thio-ketone derivative
11/29/2005US6969770 reacting an alpha-keto carboxy acid ester or derivative with a pyrrolidinone to form an intermediate, subjecting the intermediate to asymmetric hydrogenation using a chiral catalyst to form the end product
11/29/2005US6969728 Antiinflammatory agents
11/29/2005US6969727 Obesity; osteoporosis
11/29/2005US6969726 can be used as anti-proliferative agents and/or anti-infective agents that can be used without limitation as anti-inflammatory agents
11/29/2005US6969715 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
11/29/2005US6969714 Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
11/29/2005US6969713 Piperidine and piperazine acetamide derivatives
11/29/2005CA2420329C Sulphonylaminocarbonyltriazolinones
11/24/2005WO2005111024A1 Pyrimidine derivatives for the treatment of abnormal cell growth
11/24/2005WO2005111023A1 Pyrimidine derivatives for the treatment of abnormal cell growth
11/24/2005WO2005111022A1 Pyrimidines derivatives for the treatment of abnormal cell growth
11/24/2005WO2005111021A1 Preparation of candesartan cilexetil in high purity
11/24/2005WO2005111020A2 Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
11/24/2005WO2005111019A1 Novel pyridazinone derivatives as inhibitors of cdk2
11/24/2005WO2005111018A1 Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
11/24/2005WO2005111003A1 Amino-tetrazoles analogues and methods of use
11/24/2005WO2005111001A1 Novel fused heterocycles and uses thereof
11/24/2005WO2005110998A1 Scalable synthesis of imidazole derivatives
11/24/2005WO2005110996A1 Novel cis-imidazolines
11/24/2005WO2005110992A1 Amido compounds and their use as pharmaceuticals
11/24/2005WO2005110986A1 Hydroformylation process for pharmaceutical intermediate
11/24/2005WO2005110416A2 4,5-disubstituted-2-aryl pyrimidines
11/24/2005WO2005109987A2 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders
11/24/2005WO2005087722A9 Diphenylmethyl compounds useful as muscarinic receptor antagonists
11/24/2005WO2005068453A3 Crystalline forms of rizatriptan benzoate
11/24/2005WO2005046604A3 Heteroaryl-hydrazone compounds
11/24/2005US20050261501 e.g. 1-({[9-(hydroxymethyl)-3-oxaspiro[5.5]undec-9-yl]amino}acetyl)-2-pyrrolidinecarbonitrile; dipeptidyl-peptidase IV inhibitor; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity
11/24/2005US20050261496 3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide; inhibiting, modulating and/or regulating signal transduction of both receptor and non-receptor tyrosine kinases; anticarcinogenic, -diabetic, -arhtritic, -inflammatory agents; psoriasis; angiogenesisinhibitors; liver cirrhosis
11/24/2005US20050261353 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
11/24/2005US20050261352 Such as methyl 2-bromo-5-formyl-3-(3-methyl-2-buten-1-yl)-3H-imidazole-4-carboxylate
11/24/2005US20050261351 Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
11/24/2005US20050261339 Jun N-terminal kinase inhibitors; neurodegenerative diseases; Alzheimer's disease; amyotrophic lateral sclerosis; multiple sclerosis; spinocerebellar ataxia
11/24/2005US20050261324 Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4
11/24/2005US20050261322 HIV integrase inhibitors
11/24/2005US20050261319 Novel 2-amino-4-quinazolinones and 2-amino-4-oxoquinazolones as LXR nuclear receptor binding compounds with partial agonistic properties
11/24/2005US20050261318 Protein kinase inhibitors
11/24/2005US20050261317 Inhibitors of human phosphatidylinositol 3-kinase delta
11/24/2005US20050261311 Piperizinones as modulators of chemokine receptor activity
11/24/2005US20050261309 Imidazole compounds
11/24/2005US20050261296 Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
11/24/2005US20050261295 Pyrimidine as PLK inhibitors
11/24/2005US20050261294 Substituted heteroaryl derivatives, compositions, and methods of use
11/24/2005US20050261293 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/24/2005US20050261290 Novel compounds of proline and morpholine derivatives
11/24/2005US20050261288 Tetracyclic lactam derivatives and uses thereof
11/24/2005US20050261287 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
11/24/2005US20050261271 Dipeptidyl peptidase inhibitors
11/24/2005US20050261268 For therapy of allergic disorders, proliferative disorders, autoimmune disorders, conditions associated with organ transplant, inflammatory disorders, immunologically mediated disorders, viral diseases, or destructive bone disorders
11/24/2005US20050261176 Compositions and methods relating to novel compounds and targets thereof
11/24/2005DE102004021779A1 Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel New beta-agonists, to processes for their preparation and their use as medicaments
11/24/2005CA2567154A1 Novel pyridazinone derivatives as inhibitors of cdk2
11/24/2005CA2566707A1 Pyrimidine derivatives for the treatment of abnormal cell growth
11/24/2005CA2566477A1 Pyrimidine derivatives for the treatment of abnormal cell growth
11/24/2005CA2566332A1 Pyrimidine derivatives for the treatment of abnormal cell growth
11/24/2005CA2565514A1 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders
11/24/2005CA2565238A1 Amido compounds and their use as pharmaceuticals
11/24/2005CA2565211A1 Amino-tetrazoles analogues and methods of use
11/24/2005CA2565189A1 Cis-2,4,5-triphenyl imidazolines and their use as anti-cancer medicaments
11/24/2005CA2563607A1 4,5-disubstituted-2-aryl pyrimidines
11/24/2005CA2562597A1 Preparation of candesartan cilexetil in high purity
11/23/2005EP1598350A1 Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis
11/23/2005EP1598348A1 Novel pyridazinone derivatives as inhibitors of CDK2
11/23/2005EP1598343A1 2-Arylaminopyrimidine derivatives as PLK inhibitors
11/23/2005EP1598340A1 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598339A1 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598338A1 1-(4-piperidinyl)-1,3-dihydro-2h-indole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598067A1 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
11/23/2005EP1597254A1 Indole-derivative modulators of steroid hormone nuclear receptors
11/23/2005EP1597251A2 Pyrimidine compounds
11/23/2005EP1597250A2 Indolylmaleimide derivatives
11/23/2005EP1597244A1 Ethynyl derivatives serving as factor xa inhibitors
11/23/2005EP1597235A1 Non-nucleoside reverse transcriptase inhibitors
11/23/2005EP1597229A2 Pyrrolidine derivatives as oxytocin antagonists
11/23/2005EP1597228A2 Substituted n-arylheterocycles, method for production and use thereof as medicaments
11/23/2005EP1503754B1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
1 ... 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 ... 626